Post-CoreValve pacemaker use may be on the decline
Decreasing rates of pacemaker implantation in patients who have undergone TAVI procedures with Medtronic's CoreValve may hint at solutions to the "pacemaker issue."
One in 4 patients who received Medtronic's (NYSE:MDT) CoreValve system between Dec. 2007 and March 2012 also received a pacemaker to counter complications following the procedure, but that's down from earlier reports and new strategies may push rates even lower.
Just a year-and-a-half ago reports from the U.K. concluded that 1 in 3 CoreValve patients required a pacemaker within 30 days of the procedure, higher than seen with rival Edwards Lifesciences' (NYSE:EW) Sapien valve.
Physicians have come up with a handful of strategies that may reduce the need for patients to receive pacemakers alongside heart valves, posing a potential solution to what some call the "pacemaker issue."